维奈克拉联合R-或G-CHOP治疗非霍奇金淋巴瘤:CAVALLI 1b期试验结果
CAVALLI 1b期研究在56例B细胞非霍奇金淋巴瘤患者中评估维奈克拉联合R-CHOP或G-CHOP的安全性并确定2期推荐剂量。总体缓解率均为87.5%,完全缓解率分别为79.2%和78.1%。R-CHOP联合维奈克拉的2期推荐剂量为800 mg第1周期第4-10天、第2-8周期第1-10天。
要点
- 维奈克拉联合R-CHOP的2期推荐剂量为800 mg第1周期第4-10天、第2-8周期第1-10天。
- 总体缓解率87.5%(R-CHOP和G-CHOP联合组),完全缓解率分别为79.2%和78.1%。
- 双表达(BCL2+和MYC+)DLBCL患者中87.5%(n=7/8)达到完全缓解。
核心结论
- 维奈克拉联合R-CHOP的2期推荐剂量为800 mg第1周期第4-10天、第2-8周期第1-10天,该给药方案安全性可接受。
- 未达到最大耐受剂量,未探索更高剂量。
- 该方案随后在研究的2期部分中用于初治DLBCL的评估。
研究设计与样本
- 1b期研究,剂量递增维奈克拉联合利妥昔单抗或奥妥珠单抗及环磷酰胺、多柔比星、长春新碱、泼尼松(R-/G-CHOP)化疗治疗B细胞非霍奇金淋巴瘤。
- 共入组56例患者,多数为滤泡性淋巴瘤(43%)或弥漫性大B细胞淋巴瘤(DLBCL;32%)。
- 研究目标包括安全性评估和确定2期推荐剂量。
- 试验注册号NCT02055820。
主要发现
- 首个维奈克拉剂量(200 mg/d)时14例患者中3例报告剂量限制性毒性,此后给药从每日改为每周期10天并递增至800 mg。
- G-CHOP组在800 mg剂量水平进一步减少至每周期5天。
- 3/4级事件以血细胞减少为主,报告率高于预期,尤其在G-CHOP组;但安全性可控。
- 总体缓解率87.5%(R-CHOP和G-CHOP联合组);完全缓解率分别为79.2%和78.1%。
- 双表达(BCL2+和MYC+)DLBCL患者中87.5%(n=7/8)达到完全缓解。
关键数值与推荐
- 维奈克拉联合R-CHOP的2期推荐剂量:800 mg,第1周期第4-10天,第2-8周期第1-10天。
- 首个维奈克拉剂量200 mg/d时14例中3例报告剂量限制性毒性。
- 总体缓解率87.5%(R-CHOP和G-CHOP联合组);完全缓解率R-CHOP组79.2%、G-CHOP组78.1%。
- 双表达(BCL2+和MYC+)DLBCL患者完全缓解率87.5%(n=7/8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未达到最大耐受剂量,未探索更高剂量。
- 3/4级血细胞减少报告率高于预期,尤其在G-CHOP组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Objectives included safety assessment and determination of a recommended phase 2 dose (RP2D). Fifty-six patients were enrolled, most with follicular lymphoma (43%) or diffuse large B-cell lymphoma (DLBCL; 32%). Dose-limiting toxicities were reported in 3/14 patients at the first venetoclax dose (200 mg/d), after which dosing was changed from daily to 10 days per cycle and escalated to 800 mg. A further reduction to 5 days per cycle occurred at the 800-mg dose level in the G-CHOP arm. Cytopenias were predominant among grade 3/4 events and reported at a higher rate than expected, particularly in the G-CHOP arm; however, safety was manageable. Overall response rates were 87.5% (R-CHOP and G-CHOP combinations); complete response (CR) rates were 79.2% and 78.1%, respectively. Most double-expressor (BCL2+ and MYC+) DLBCL patients (87.5%; n = 7/8) achieved CR. Although the maximum tolerated dose was not reached, the RP2D for venetoclax with R-CHOP was established at 800 mg days 4 to 10 of cycle 1 and days 1 to 10 of cycles 2 to 8; higher doses were not explored, and this dosing schedule demonstrated an acceptable safety profile. This regimen is subsequently being evaluated in first-line DLBCL in the phase 2 portion of the study. This trial was registered at www.clinicaltrials.gov as #NCT02055820.
引用
- Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019. PMID: 30850381. doi:10.1182/blood-2018-11-880526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。